INmune Bio Inc (INMB): Next-Year EPS Estimate 40.69%
As of 2026-03-30, INmune Bio Inc (INMB) has a next-year EPS growth estimate of 40.69%.
On 2026-03-20, analyst consensus for INMB's next-year EPS growth shifted from 65.48% to 40.69% — a negative change of 24.79 percentage points. The revised estimate has been sustained across 17 subsequent trading sessions.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 40.69%
- EPS growth this year
- N/A
- EPS next quarter (est)
- N/A
- Last price
- $1.14
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-03-30 | 40.69% | N/A | N/A | $1.14 |
| 2026-03-30 | 40.69% | N/A | N/A | $1.14 |
| 2026-03-30 | 40.69% | N/A | N/A | $1.14 |
| 2026-03-29 | 40.69% | N/A | N/A | $1.12 |
| 2026-03-29 | 40.69% | N/A | N/A | $1.12 |
| 2026-03-27 | 40.69% | N/A | N/A | $1.12 |
| 2026-03-26 | 40.69% | N/A | N/A | $1.20 |
| 2026-03-26 | 40.69% | N/A | N/A | $1.20 |
| 2026-03-26 | 40.69% | N/A | N/A | $1.20 |
| 2026-03-25 | 40.69% | N/A | N/A | $1.22 |
| 2026-03-25 | 40.69% | N/A | N/A | $1.22 |
| 2026-03-25 | 40.69% | N/A | N/A | $1.22 |
| 2026-03-24 | 40.69% | N/A | N/A | $1.18 |
| 2026-03-24 | 40.69% | N/A | N/A | $1.18 |
| 2026-03-24 | 40.69% | N/A | N/A | $1.18 |
| 2026-03-23 | 40.69% | N/A | N/A | $1.24 |
| 2026-03-20 | 40.69% | N/A | N/A | $1.17 |
| 2026-03-19 | 65.48% | N/A | N/A | $1.22 |
| 2026-03-18 | 40.69% | N/A | N/A | $1.24 |
| 2026-03-17 | 40.69% | N/A | N/A | $1.28 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is INmune Bio Inc's next-year EPS growth estimate?▾
As of 2026-03-30, INmune Bio Inc (INMB) has a next-year EPS growth estimate of 40.69%, based on analyst consensus.
When was the latest EPS estimate revision for INMB?▾
The most recent revision occurred on 2026-03-20, when analysts adjusted the next-year EPS growth estimate from 65.48% to 40.69%.
What sector and industry does INmune Bio Inc belong to?▾
INmune Bio Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. INMB appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. INmune Bio Inc (INMB) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports